(2R,3R)-2,3-双[(4-甲基苯甲酰基)氧基]丁二酸和 (3R,4R)-N,4-二甲基-1-(苯基甲基)-3-哌啶胺的化合物

(2R,3R)-2,3-双[(4-甲基苯甲酰基)氧基]丁二酸和 (3R,4R)-N,4-二甲基-1-(苯基甲基)-3-哌啶胺的化合物性质、用途与生产工艺

用途

(2R,3R)-2,3-双[(4-甲基苯甲酰基)氧基]丁二酸和 (3R,4R)-N,4-二甲基-1-(苯基甲基)-3-哌啶胺的化合物用作有机合成，可用于实验室研发过程和化工医药合成过程中。

(2R,3R)-2,3-双[(4-甲基苯甲酰基)氧基]丁二酸和 (3R,4R)-N,4-二甲基-1-(苯基甲基)-3-哌啶胺的化合物 上下游产品信息

上游原料

下游产品

(2R,3R)-2,3-双[(4-甲基苯甲酰基)氧基]丁二酸和 (3R,4R)-N,4-二甲基-1-(苯基甲基)-3-哌啶胺的化合物 生产厂家

477600-71-8, (2R,3R)-2,3-双[(4-甲基苯甲酰基)氧基]丁二酸和 (3R,4R)-N,4-二甲基-1-(苯基甲基)-3-哌啶胺的化合物 相关搜索:

• 209-5B
• 化工中间体
• 化学试剂
• 化工原料及中间体
• 现货
• 芳基类化合物
• 医药原料中间体
• 系列1
• 枸橼酸托法替尼相关中间体
• 中间体
• 医药中间体
• 化学试剂、精细化学品、医药中间体、材料中间体
• C20H18O82C14H22N2
• methylbenzoyl)oxy)succinate) (2:1)
• bis-(3R,4R)-(1-benzyl-4-methyl-piperidin-3-yl)-
• 顺式-1-苄基-4-甲基-3-甲氨基-哌啶L-DTTA盐,托伐替尼中间体
• ((3R,4R)-1-苄基-N,4-二甲基哌啶-3-胺((2R,3R)-2,3-二((4-甲基苯甲酰基)氧基)琥珀酸盐
• 托法替尼杂质170
• 二((3R,4R)-1-苯甲基-N,4-二甲基哌啶-3-胺)
• (2R,3R)-2,3-二(4-甲基苯甲酰氧基)丁二酸
• (3R,4R)-N,4-二甲基-1-(苯基甲基)-3-氨基哌啶-半-(2R,3R)-2,3-双[(4-甲基苯甲酰基)氧基]丁二酸盐
• (2R,3R)-2,3-双[(4-甲基苯甲酰基)氧基]丁二酸和 (3R,4R)-N,4-二甲基-1-(苯基甲基)-3-哌啶胺的化合物/(3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE ((2R,3R)-2,3-BIS((4-METHYLBENZOYL)OXY)SUCCINATE) (2:1)
• (2R,3R)-2,3-双[(4-甲基苯甲酰基)氧基]丁二酸和 (3R,4R)-N,4-二甲基-1-(苯基甲基)-3-哌啶胺
• (3R,4R)-1-苄基-N,4-二甲基哌啶-3-氨-L-(-)-对甲基二苯甲酰酒石酸盐
• (2R,3R)-2,3-双[(4-甲基苯甲酰基)氧基]丁二酸和 (3R,4R)-N,4-二甲基-1-(苯基甲基)-3-哌啶胺的混合物
• (4R)-1-苄基-N,4-二甲基哌啶-3-胺1-苄基-N,4-二甲基哌啶-3-胺半((2R,3R)
• ((3R,4R)-1-苄基-N,4-二甲基哌啶-3-胺((2R,3R)-2,3-二((4-甲基苯甲酰基)氧基)琥珀酸盐)(2:1)
• (2R,3R)-2,3-双[(4-甲基苯甲酰基)氧基]丁二酸和 (3R,4R)-N,4-二甲基-1-(苯基甲基)-3-哌啶胺的化合物
• 477600-71-8
• (2R,3R)-2,3-pair [(4-Methylbenzoyl)Oxygen]Succinic acid and (3R,4R)-N,4-dimethyl- 1-(phenylmethyl)-3-Piperidinamine compounds
• hemi((2R,3R)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid) - [B15038]
• (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine (1:2)
• BAP-L-Tartrate
• (2R,3R)-2,3-Bis[(4-methylbenzoyl)oxy]butanedioic acid compd. with (3R,4R)-N,4-dimethyl-1-(phenylmethyl)-3-piperidinamine
• 3R)-2
• hemi((2R,3R)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid)
• Tofacitinib Impurity 170
• (2R,3R)-2,3-Bis[(4- methylbenzoyl)oxy]succinic acid - (3R,4R)-1-benzyl-N,4-dimethyl- 3-piperidinamine (1:2)
• Bis (3R,4R)-N,4-dimethyl-1-(phenylmethyl)-3-piperidinamine di Toluyl L-Tartrate
• 3-bis(4-Methylbenzoyloxy)succinate) tert-butyl ester
• TOFACITINIB CITRATE CAS 540737-29-9
• (3-R,4R)1-1BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE (2R,3R)-2,3-BIS(4-METHYLBENZOYL)OXY)SUCCINATE
• (3R,4R)-1-benzyl-N-dimethylpiperidin-3-amine (1:2)
• (2R, 3R) -2,3-bis [(4-methylbenzoyl) oxy] succinic acid and (3R, 4R) -N, 4-dimethyl-1- (phenylmethyl) 3-Piperidine amine compound
• (2R,3R)-2,3-Bis[(4-methylbenzoyl)oxy]
• (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine-(-)-Di-p-toluoyl-(L)-tartaric acid monohydrate salt
• -2,3-bis((4-methylbenzoyl)
• -1-Benzyl-N,4-dimethylpiperidin-3-amine ((2R,3R)
• Tofacitinib intermediate 1
• Bis[(3R,4R)-N,4-dimethyl-1-(phenylmethyl)-3-piperidinamine] di-p-toluoyl-L-tartrate
• (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine,(2R,3R)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid
• bis((3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine)
• (2R,3R)-2,3-bis(4-methylbenzoyloxy)butanedioic acid
• Tofacitinib Intermediate I
• (3S,4S)-1-benzyl-N,4-diMethylpiperidin-3-aMine (2S,3S)-2,3-bis((4-Methylbenzoyl)oxy)succinic acid
• (3R,4R)-1-Benzyl-N,4-diMethylpiperidin-3-aMine ((2R,3R)-2,3-bis((4-Methylbenzoyl)oxy)succinate) (2:1)
• Bis[(3R,4R)-N,4-diMethyl-1-(phenylMethyl)-3-piperidinaMine] di-p-toluyl-L-tartrate
• Butanedioic acid, 2,3-bis[(4-Methylbenzoyl)oxy]-, (2R,3R)-, coMpd. with (3R,4R)-N,4-diMethyl-1-(phenylMethyl)-3-piperidinaMine (1:2)